XEOMIN® Efficacy | Upper Limb Spasticity

Adults With Upper Limb Spasticity

What's It Like Being An Adult With Upper Limb Spasticity?

Significant Difference Was Seen in the Mean Change on the Ashworth Scale Between XEOMIN and Placebo (P<0.001)1

  • Investigators evaluated 3 total primary target clinical patterns: flexed wrist, flexed elbow, or clenched fist1
  • XEOMIN patients showed significant improvement in muscle tone as measured by the Ashworth Scale vs placebo at Week 41
    • Ashworth Scale is a clinical measure of the severity of spasticity by judging resistance to passive movement1
XEOMIN® demonstrated improvements in muscle tone. Pinch to zoom

*The analysis is based on last observation carried forward in the full analysis set.

The Investigators’ Global Impression of Change Scale (GICS) Scores at Week 4 Demonstrated That XEOMIN Was Superior to Placebo1

  • XEOMIN patients had improvements in overall upper limb spasticity as measured by GICS (mean GICS score for XEOMIN was 0.3 points higher than placebo at Week 4; P<0.003)1
    • GICS is a global measure of a patient’s functional improvement1
    • Investigators were asked to evaluate the patients‘ global change in spasticity of the upper limb due to treatment, compared to the condition before the last injection1
XEOMIN® improved patient’s functional improvement. Pinch to zoom


  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.